NASDAQ$EQ
Equillium Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Announced financial results for the second quarter 2020.
Equillium reported a net loss of $6.5 million for Q2 2020, or $(0.37) per basic and diluted share. The company held $42.6 million in cash, cash equivalents, and short-term investments as of June 30, 2020.
- Reported positive interim data from EQUATE clinical trial of itolizumab as a first line therapy for patients with aGVHD – 71% of patients treated to date achieved a complete response at Day 29
- Shared encouraging topline results as reported by Biocon from their randomized, controlled open label clinical trial conducted in India showing itolizumab (ALZUMAb) reduced mortality over one month as compared to placebo in patients hospitalized with COVID-19.
- Submitted a pre-investigational new drug (pre-IND) meeting request and supporting briefing package to the U.S. Food and Drug Administration (FDA) to study itolizumab in hospitalized patients with COVID-19
- Strengthened the balance sheet by raising a total of approximately $17.9 million in gross proceeds subsequent to the end of the second quarter 2020
Headline financials
Revenue & EPS history
Equillium · Revenue · Quarterly
$0
Forward guidance
Equillium is initiating a global trial of itolizumab in hospitalized patients with COVID-19 and advancing ongoing EQUATE, EQUIP and EQUALISE trials.
Tailwinds
- Initiation of a global trial of itolizumab in hospitalized patients with COVID-19
- Advancing ongoing EQUATE trial
- Advancing ongoing EQUIP trial
- Advancing ongoing EQUALISE trials
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2020
+1.0%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-1.3%
Avg return
30 days after
55%
17 / 31 earnings
Positive
+42.0%
Q3 2020
Best reaction
-27.0%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.8% | -18.9% | — | |
| Q3 2025 | +23.8% | +20.2% | +52.4% | |
| Q2 2025 | +16.3% | +16.3% | +90.8% | |
| Q1 2025 | +5.4% | +5.4% | -5.4% | |
| Q1 2026 | +5.4% | +5.4% | -5.4% | |
| Q4 2024 | -2.5% | -10.0% | -16.0% | |
| Q3 2024 | -19.5% | -20.0% | -17.6% | |
| Q2 2024 | -4.6% | +0.0% | +27.4% | |
| Q1 2024 | -10.0% | -9.4% | -52.9% | |
| Q4 2023 | -27.0% | -18.1% | -36.5% | |
| Q3 2023 | -1.8% | +0.0% | +22.0% | |
| Q2 2023 | +3.9% | +2.6% | +6.5% | |
| Q1 2023 | +3.6% | +7.1% | +17.9% | |
| Q4 2022 | +12.3% | +10.8% | -4.6% | |
| Q3 2022 | +6.5% | +5.9% | -28.2% | |
| Q2 2022 | +1.4% | -1.8% | -25.5% | |
| Q1 2022 | +3.7% | +13.8% | +0.0% | |
| Q4 2021 | +0.0% | -9.1% | -10.3% | |
| Q3 2021 | -13.6% | -14.5% | -27.0% | |
| Q2 2021 | +2.7% | +2.2% | -2.4% | |
| Q1 2021 | +6.1% | +22.3% | +19.0% | |
| Q4 2020 | -8.5% | -12.7% | -19.5% | |
| Q3 2020 | +42.0% | +27.6% | +34.1% | |
| Q2 2020 | -12.8% | -29.7% | -45.0% | |
| Q1 2020 | -14.9% | -20.6% | -19.7% | |
| Q4 2019 | -1.1% | +2.3% | +7.5% | |
| Q3 2019 | -1.2% | +7.1% | +45.7% | |
| Q2 2019 | -0.5% | +7.1% | -0.5% | |
| Q1 2019 | +2.0% | +2.5% | +0.3% | |
| Q4 2018 | +6.1% | +9.2% | -20.2% | |
| Q3 2018 | +6.4% | -8.7% | -24.5% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro